Galectin-3 levels are elevated following nintedanib treatment

• Main Authors: Gali Epstein Shochet (Author), Alon Pomerantz (Author), David Shitrit (Author), Becky Bardenstein-Wald (Author), Kjetil Ask (Author), Mark Surber (Author), Noa Rabinowicz (Author), Yair Levy (Author), Sydney Benchetrit (Author), Evgeny Edelstein (Author), Tali Zitman-Gal (Author)
• Format: Book
• Published: SAGE Publishing, 2020-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background and Aims: Idiopathic pulmonary fibrosis (IPF) is a common and severe form of pulmonary fibrosis. Nintedanib, a triple angiokinase inhibitor, is approved for treating IPF. Galectin 3 (Gal-3) activates a variety of profibrotic processes. Currently, the Gal-3 inhibitor TD139 is being tested...